Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053523 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL17112600 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL14222418 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| SCHEMBL584860 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112575 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL1394716 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL31128136 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL17112628 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Hydrochloric Acid SCHEMBL19741915 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 | |
| Bicarbonate SCHEMBL9225058 | 0.96 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112375267-A | Modified zinc oxide/rubber composite material and preparation method thereof | 侯光宇 | 2021-02-19 | — | — | CN | claimed |
| CN-111944289-A | PBAT/PLA composite material for degradable garbage bag and preparation method thereof | 张文俊 | 2020-11-17 | — | — | CN | claimed |
| CN-111808322-A | Modified ammonium polyphosphate material for antibacterial flame-retardant carpet and preparation method thereof | 浙江红励卓纺织有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-111688306-A | Flame-retardant and waterproof polypropylene SMS composite non-woven fabric | 浙江景程无纺布有限公司 | 2020-09-22 | — | — | CN | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2009019286-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167468-A1 | SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE | GPR119, INSR, GCKR | CHRNB2 4558/4885CHRNA4 4791/4885CHRNB4 4863/4885 |
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | CHRNB2 3071/4885CHRNA4 3019/4885CHRNB4 3551/4885 |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | NRAS, KRAS, HRAS | CHRNB2 4527/4885CHRNA4 4610/4885CHRNB4 4313/4885 |
| US-20080085884-A1 | Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones | MCHR1, MCHR2, MC1R | CHRNB2 726/4885CHRNA4 824/4885CHRNB4 942/4885 |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | CHRNB2 427/4885CHRNA4 582/4885CHRNB4 552/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | CHRNB2 4706/4885CHRNA4 4815/4885CHRNB4 4775/4885 |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | CHRNB2 3334/4885CHRNA4 2882/4885CHRNB4 3108/4885 |
| US-20260109707-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, AR, BRDT | CHRNB2 1024/4885CHRNA4 403/4885CHRNB4 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.